Intercytex Group Plc said that it does not expect to receive an offer for the company as a whole, and therefore is further winding down its activities and reducing staff. Discussions over the sale of certain parts of the business are ongoing.
ReNeuron Group Plc, which cut its total expenses by about a third in the most recent financial year, has pinned its future on making the company’s neural stem cell therapy for stroke a success.
Alizyme Plc has told investors that there is a “material uncertainty” about whether it will receive milestone payments for one of its drug development programmes. Barring additional funding, it would therefore be unable to continue as a going concern.
Neovacs SA, a small, privately owned biologics company in Paris, is developing third generation antibodies, which are currently defined as vaccines that cause the body will make its own antibodies to whatever target is required.
Eli Lilly has launched a new web-based initiative to capture independent drug research from universities and biotechnology companies that might eventually form the basis for future collaborations or licensing deals.
GW Pharmaceuticals Plc, which has a cannabinoid product for multiple sclerosis in registration in Europe, has entered an exclusive strategic alliance with a professor at the University of Buckingham to investigate cannabinoids for metabolic disease.
Boehringer Ingelheim of Germany has announced plans to collaborate with the privately-held US firm, Vitae Pharmaceuticals Inc, to investigate beta-secretase inhibitors for the treatment of Alzheimer’s disease.
A US company with novel technology for making peptide drugs has received $40 million in a Series D funding from a syndicate that includes the venture capital arms of four major pharmaceutical companies.
In a second collaboration between two Big Pharma companies this year, AstraZeneca Plc and Merck & Co have announced plans to investigate the possible use of their respective, early-stage cancer treatments together, as a co-administered treatment.
GlaxoSmithKline has announced a collaboration worth up to $1 billion with Concert Pharmaceuticals of Lexington, Mass, involving the use of deuterium chemistry to create novel small molecule drugs.